Dhuumaha

Sorrento's R&D wuxuu diiradda saarayaa wadida hal-abuurka COVID-19, daaweynta kansarka, xakameyn buuxda oo xanuunka iyo cudurrada difaaca jirka

Barnaamijyada Muhiimka ah Muujin Diyaarsanaan Wejiga I Wajiga labaad Marxaladda III/Pivotal FDA Approval
Barnaamijyada COVID-19  

COVISTIX™ (diagnostic) Tijaabada Antigen-ka degdega ah

*

Oggolaanshaha Isticmaalka Degdegga ah (EUA) ee Mexico (COFEPRIS), Brazil (ANVISA), iyo CE lagu calaamadeeyay Yurub

COVIMARK™ (diagnostic) Tijaabada Antigen-ka degdega ah

*

Codsiga lagu soo gudbiyay Mareykanka iyo Kanada ee Ogolaanshaha Isticmaalka Degdegga ah (EUA)

COVISHIELD™ (daawaynta) Dhexdhexaadinta Antibody (IN) ee Bukaan-socodka iyo Bukaan-jiifka

40%*

COVISHIELD™ (daawaynta) Dhexdhexaadinta Antibody (IV) ee Bukaan-socodka iyo Bukaan-jiifka

20%*

FUJOVEE™ (Abivertinib) COVID-19 daran oo ku jira Bukaanka ICU

82%*

Tijaabada Muhiimka ah ee la sugayo nadiifinta FDA

OQORY™ (COVI-MSC) ARDS oo ay ugu wacan tahay COVID-19 ee Bukaannada ICU

82%*

Tijaabada Muhiimka ah ee Brazil

Mpro Kahortagga (kaniiniga afka) Anti-viral

40%*

Omicron mRNA Tallaalka Tallaalka

20%*

Barnaamijyada Muhiimka ah Muujin Diyaarsanaan Wejiga I Wajiga labaad Marxaladda III/Pivotal FDA Approval
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) Lymphomas Unugyada B

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*Iskaashiga Lee's Pharm ee Shiinaha

PD-L1 (STI-3031)** Kansarka afka ilmo-galeenka

82%*

** gudaha Maraykanka iyo iyada oo lala kaashanayo ImmuneOncia ee Kuuriya

CD47 Burooyin Adag

40%*

CD38 DAR-T Meelo badan

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, iyo hunguriga

40%*

TROP2 ADC* Burooyin Adag

40%*

* Shiinaha

Seprehvec™ oncolytic fayraska Burooyinka adag; Burooyinka CNS

40%*

BCMA ADC Burooyinka dareeraha ah

20%*

Bevacizumab-ADNAB™ Kansarka endometrial

40%*

Iyadoo lala kaashanayo Mayo Clinic

Bevacizumab-ADNAB™ Kansarka Ovarian

40%*

Iyadoo lala kaashanayo Mayo Clinic

Rituximab-ADNAB™ Lymphomas-unugyada B

40%*

Iyadoo lala kaashanayo Mayo Clinic
Barnaamijyada Muhiimka ah Muujin Diyaarsanaan Wejiga I Wajiga labaad Marxaladda III/Pivotal FDA Approval
Xanuun  

ZTlido™ 1.8%
Neuralgia postherpetic - PHN

99.8%*

SP-102 (SEMDEXA) Lumbar Radicular/Sciatica Xanuun

82%*

SP-103 (Nidaamka Mawduuca Lidocaine 5.4%) Dhabar-xanuun daran

20%*

SP-104 (Qiyaas hoose oo Naltrexone ah oo dillaacay oo daahay) fibromyalgi

20%*

RTX (resiferatoxin)
Cirbadda epidural
Xannuun aan la daweyn karin oo ku jira Kansarka Sare

60.3%*

Magacaabista agoonta

RTX (resiferatoxin)
Dariiqa articular
Dhexdhexaad ilaa Daran OA Xanuun Jilibka ah

60.2%*

Barnaamijyada Muhiimka ah Muujin Diyaarsanaan Wejiga I Wajiga labaad Marxaladda III/Pivotal FDA Approval
Bixinta Lymphatic  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cudurka T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

Iyadoo lala kaashanayo Mayo Clinic
Barnaamijyada COVID-19
Barnaamijyada Muhiimka ah (Tilmaan) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
COVISHIELD™ (daawaynta) PH I
COVISHIELD™ (daawaynta) Diyaarsanaan
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (kaniiniga afka) (ka-hortagga fayraska) Ph I
Omicron mRNA Tallaalka (tallaal) Diyaarsanaan
immunotherapy
Barnaamijyada Muhiimka ah (Tilmaan) Phase
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) (Lymphomas Unugyada B) Ph II
FUJOVEE™ (Abivertinib) (Prostate) Diyaarsanaan
FUJOVEE™ (Abivertinib) (Lupus) Diyaarsanaan
FUJOVEE™ (Abivertinib) (MS) Diyaarsanaan
FUJOVEE™ (Abivertinib) (GvHD) Diyaarsanaan
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Kansarka ilmo-galeenka) Ph III
CD47 (Buro Adag) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, iyo hunguriga) Ph I
TROP2 ADC* (Buro Adag) Ph I
Seprehvec™ oncolytic fayraska (Buro adag; Burooyinka CNS) PH I
BCMA ADC ( Burooyinka dareeraha ah) Diyaarsanaan
Bevacizumab-ADNAB™ Kansarka endometrial Ph I
Bevacizumab-ADNAB™ (Kansarka ugxansidaha) Ph I
Rituximab-ADNAB™ (Lymphomas B-cell) Ph I
Xanuun
Barnaamijyada Muhiimka ah (Tilmaan) Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
SP-102 (SEMDEXA) Ph III
SP-103 (Nidaamka Mawduuca Lidocaine 5.4%) Diyaarsanaan
SP-104 (Qiyaas hoose oo Naltrexone ah oo dillaacay oo daahay) Diyaarsanaan
RTX (resiniferatoxin) cirbadeynta epidural (Xanuun aan la daweyn karin oo ku jira Kansarka Sare) Ph II
RTX (resiniferatoxin) Dariiqa xididada hoose (Dhexdhexaad ilaa Daran OA Xanuun Jilibka ah) Ph II
Bixinta Lymphatic
Barnaamijyada Muhiimka ah (Tilmaan) Wajiga labaad
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I